antiaging

Aniracetam as Nootropic, Anti-Dementia Drug and Anxiolytic

 

ani

Aniracetam is a fat soluble cousin of piracetam. It is non-toxic and non-addictive. It is a quantitatively and qualitatively more powerful nootropic than piracetam. Lab mice given standard doses of either drug perform better than control groups, but aniracetam-fed mice, including the dimwitted D2 variety, perform better on a wider range of cognitive tests, suggesting aniracetam  has greater therapeutic potential than piracetam. In a study conducted on 100 elderly patients showing signs of  Alzheimers or dementia ” the aniracetam group differed significantly from the placebo group by the end of the study and also showed a statistically significant improvement versus baseline in the psychobehavioural parameters, while in the placebo group a steady deterioration was observed. Tolerability to aniracetam was excellent.”

From the (translated) manufacturer’s label:

“This is an original pharmaceutical product by Roche, which acts on the central nervous system (CNS), stimulating the learning process and the memory. Pharmacological studies have shown that Aniracetam stimulates the functions of certain neuronal receptors by means of glutamic acid, bringing about memorization processes (AMPA receptors) and protection of nerve cells (metabotrophic receptors). Clinical studies have shown specific therapeutic activity in elderly patients affected by alterations of the cognitive functions. Both long and short term memory improvement have seen in addition to learning, attention span, alertness, concentration, reasoning and absent mindedness.”

As or more interesting are aniracetam’s anxiolytic properties and its potential as a pro-social drug. Drug makers have been searching for the holy grail of anxiety suppressants for some time. Benzodiazpenes, which come with a slue of nasty side effects including memory impairment and dependence, seem unattractive compared to this orphaned pharmaceutical. For although research continues to be done, the medical community still seems largely uninterested and unaware. Outside of the arcane realm of psychoneuropharmacology, aniracetam has attracted the attention of a growing group of people fascinating by the possibilities intelligence amplification holds for homo sapiens.

“In a social interaction test in which all classes (serotonergic, cholinergic and dopaminergic) of compounds were effective, aniracetam (10-100 mg/kg) increased total social interaction scores (time and frequency), and the increase in the total social interaction time mainly reflected an increase in trunk sniffing and following…Aniracetam also showed anti-anxiety effects in two other anxiety models (elevated plus-maze and conditioned fear stress tests), whereas diazepam as a positive control was anxiolytic only in the elevated plus-maze and social interaction tests.”

There has yet to be a clinical trial to test its usefulness as an anxiety medication for humans, however there is a substantial body of anecdotal evidence already and it seems likely in this instance its effects on mice can are the same for other mammals. A user on Longecity reports:

“Aniracetam, especially in high doses, produces the strongest effects I’ve experienced from nootropics as of yet. A single two-four gram dose (common for me) of aniracetam starts to affect my mind in about 45-60min after oral ingestion. It then peaks after about 90min, and goes down some 2-4hours after ingestion. My mind gradually seems to accept all my stressful and anxious thoughts of the day, and I feel truly at peace with my environment, internal and external. Often this involves me sitting down, barely moving because of my extreme satisfaction, and watching my mind and body heal.”

This is not an uncommon experience. It is unfortunate pharmaceutical grade aniracetam is not widely available; it more unfortunate that the companies currently supplying it are not regulated by the FDA (although some are kind enough to offer independent laboratory analyses of their products). Its time will come.

New Effective Nootropics

For a Brighter Future

 

Bartolini, L., F. Casamenti, and G. Pepeu. “Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions.” Pharmacology Biochemistry and Behavior 53.2 (1996): 277-283.
Greenblatt, David J., and Richard I. Shader. “Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations.” Drug metabolism reviews 8.1 (1978): 13-28.
Martin, J. R., and W. E. Haefely. “Pharmacology of Aniracetam.” Drug Investigation 5.1 (1993): 4-49.
Roth, T., et al. “Benzodiazepines and memory.” British journal of clinical pharmacology 18.S1 (1984): 45S-49S.
 Senin, Umberto, et al. “Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study.” European Neuropsychopharmacology 1.4 (1991): 511-517.
Smith, Amy M., and Jeanne M. Wehner. “Aniracetam improves contextual fear conditioning and increases hippocampal γ‐PKC activation in DBA/2J mice.” Hippocampus 12.1 (2002): 76-85.
Vincent, George, Anthony Verderese, and Elkan Gamzu. “The effects of aniracetam (Ro 13–5057) on the enhancement and protection of memory.” Annals of the New York Academy of Sciences 444.1 (1985): 489-491.

 

Advertisements